Avasopasem
Peptideexperimental
Clinical trial activity
15 trials · 22 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01921426)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- COVID-19 · Phase 2
- Esophagitis · Phase 2
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Kidney Failure, Chronic · Phase 1
- Mucositis · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Radiation Oncology · Phase 1/Phase 2
- Stomatitis · Phase 3
Mechanism of action
- Superoxide dismutaseACTIVATOR
SOD1 activator
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gc4419
- gc4419
- gc4711
- gc4711
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07137871 | Phase 1 | Oct 2, 2025 | University of Texas, San Antonio |
| NCT04555096 | Phase 2 | Sep 9, 2020 | Galera Therapeutics |
| NCT04529850 | Phase 2 | Jun 30, 2020 | Galera Therapeutics, University of California, San Francisco |
| NCT04225026 | Phase 2 | Dec 19, 2019 | Galera Therapeutics, University of California, San Francisco |
| NCT05412472 | Phase 1 | Apr 4, 2019 | Galera Therapeutics |
| NCT03792971 | Phase 1 | Feb 10, 2019 | Galera Therapeutics |
| NCT03689712 | Phase 3 | Oct 31, 2018 | Galera Therapeutics |
| NCT03340974 | Phase 1/Phase 2 (Phase 2) | Feb 12, 2018 | Galera Therapeutics, University of Texas at Houston |
| NCT03099824 | Phase 1 | Oct 1, 2017 | Galera Therapeutics, INC Research, Nucleus Network Ltd, Projections Research, Pyxant, Labs Inc. |
| NCT03194139 | Phase 1 | Sep 1, 2017 | Galera Therapeutics, INC Research |
| NCT03164109 | Phase 1 | Aug 1, 2017 | Galera Therapeutics, INC Research |
| NCT03163173 | Phase 1 | Jul 1, 2017 | Celerion, Galera Therapeutics |
| NCT03096756 | Phase 1 | Jul 26, 2016 | Galera Therapeutics, INC Research, Nucleus Network Ltd |
| NCT02508389 | Phase 2 | Oct 1, 2015 | Clinical Assistance Programs, LLC, Galera Therapeutics, Novella Clinical |
| NCT01921426 | Phase 1 | Aug 1, 2013 | Allegheny Health Network, Cancer Care Northwest, Cancer Specialists of South Texas, P.A., Galera Therapeutics, Lakeland Regional Medical Center, Summa Health System, University of Iowa, University of Nebraska, University of Rochester, Wake Forest University, Washington University in St. Louis, Yale University |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (22)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galera Therapeutics | For profit | 14 | 14 | 3 | 2013 |
| INC Research | For profit | 4 | 0 | 1 | 2016 |
| Nucleus Network Ltd | For profit | 2 | 0 | 1 | 2016 |
| University of California, San Francisco | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Allegheny Health Network | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Cancer Care Northwest | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Cancer Specialists of South Texas, P.A. | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Celerion | For profit | 1 | 0 | 1 | 2017 |
| Clinical Assistance Programs, LLC | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Lakeland Regional Medical Center | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Novella Clinical | For profit | 1 | 0 | 1 | 2015 |
| Projections Research | For profit | 1 | 0 | 1 | 2017 |
| Pyxant, Labs Inc. | For profit | 1 | 0 | 1 | 2017 |
| Summa Health System | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Nebraska | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Wake Forest University | Academic/Hospital | 1 | 0 | 1 | 2013 |
22 organizations
Page 1 / 2